Corrigendum to 'Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis' [Eur J Cancer 47 (12) (2011) 1826–1836]

Stephen J. Clarke *, Sonia Yip , Chris Brown , Guy A. van Hazel , David T. Ransom , David Goldstein , G. Mark Jeffrey , Niall C. Tebbutt , Martin Buck , Raymond M. Lowenthal , Amy Boland , Val Gebski , John Zalcberg , R. John Simes , on behalf of the Australasian Gastro-Intestinal Trials Group a Department of Medicine, Concord Hospital, Concord, Sydney, Australia b National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, Australia c School of Medicine and Pharmacology, University of Western Australia, Perth, Australia d St. John of God Hospital, Perth, Australia e Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia f Oncology Service, Christchurch Hospital, Christchurch, New Zealand g Austin Health, Melbourne, Australia h Sir Charles Gairdner Hospital, Perth, Australia i Royal Hobart Hospital and University of Tasmania, Hobart, Australia j Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia